Pseudoprogression (PsPD) is a pathological feature recently reported by some authors in malignant glioma patients treated with radiotherapy in combination with temozolomide. In radiological imaging, it is shown as an increase in the size of the tumor lesion and contrast enhancement occurring within a few months from the completion of radio-chemotherapy without worsening of the neurological signs and symptoms. In 21%-50% of the patients, the same lesion disappears a few months after its appearance. In 12 glioblastoma patients treated with radio-chemotherapy, 4 cases of early radiological progression without discontinuation of temozolomide treatment are reported. At the sunsequent tumor assessment, 2 cases (13%) were revealed to be PsPD. The two patients who experienced PsPD had the longest progression and survival times of all patients. In both patients with PsPD, the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter was found to be methylated. The PsPD phenomenon opens the prospect of a new era for the management of glioblastoma patients undergoing radio-chemotherapy.

Pseudoprogression and MGMT status in glioblastoma patients. implications in clinical practice / Fabi, Alessandra; Russillo, Michelangelo; Metro, Giulio; Vidiri, Antonello; DI GIOVANNI, Salvatore; Cognetti, Francesco. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 29:7(2009), pp. 2607-2610.

Pseudoprogression and MGMT status in glioblastoma patients. implications in clinical practice

Russillo, Michelangelo;DI GIOVANNI, SALVATORE;Cognetti, Francesco
2009

Abstract

Pseudoprogression (PsPD) is a pathological feature recently reported by some authors in malignant glioma patients treated with radiotherapy in combination with temozolomide. In radiological imaging, it is shown as an increase in the size of the tumor lesion and contrast enhancement occurring within a few months from the completion of radio-chemotherapy without worsening of the neurological signs and symptoms. In 21%-50% of the patients, the same lesion disappears a few months after its appearance. In 12 glioblastoma patients treated with radio-chemotherapy, 4 cases of early radiological progression without discontinuation of temozolomide treatment are reported. At the sunsequent tumor assessment, 2 cases (13%) were revealed to be PsPD. The two patients who experienced PsPD had the longest progression and survival times of all patients. In both patients with PsPD, the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter was found to be methylated. The PsPD phenomenon opens the prospect of a new era for the management of glioblastoma patients undergoing radio-chemotherapy.
2009
aged; antineoplastic agents; brain neoplasms; combined modality therapy; dna modification methylases; dna repair enzymes; dacarbazine; disease progression; female; glioblastoma; humans; magnetic resonance imaging; male; middle aged; temozolomide; tumor suppressor proteins
01 Pubblicazione su rivista::01a Articolo in rivista
Pseudoprogression and MGMT status in glioblastoma patients. implications in clinical practice / Fabi, Alessandra; Russillo, Michelangelo; Metro, Giulio; Vidiri, Antonello; DI GIOVANNI, Salvatore; Cognetti, Francesco. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 29:7(2009), pp. 2607-2610.
File allegati a questo prodotto
File Dimensione Formato  
Fabi_Pseudoprogression_2009.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 162.45 kB
Formato Adobe PDF
162.45 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1311237
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 30
social impact